You are here: Industry Insights > Market News > UK regulator says COVID-19 prevention trial of hydroxychloroquine can resume

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

UK regulator says COVID-19 prevention trial of hydroxychloroquine can resume

expresspharmaJuly 01, 2020

Tag: COVID-19 , hydroxychloroquine , MHRA

Favorites

A global trial designed to find out whether the anti-malaria drug hydroxychloroquine can prevent infection with COVID-19 is to restart after getting approval from the UK medicines agency.

The Medicines and Healthcare Products Regulatory Agency (MHRA) decision on the trial, which is known as the COPCOV trial, comes after the drug was found in another UK trial to have no benefit for patients already infected with COVID-19, the pandemic disease caused by the new coronavirus.

Previous:Linagliptin demonstrates cardiovascular and renal safety in Asian adults with type 2 diabetes

Next:Novartis' Global Innovative siRNA Long-Acting Lipid-lowering Therapy Submitted Clinical Application in China

InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

PharmaSourcesApril 28, 2024

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases.

Touchlight Awarded Grant Extension to Further Develop DNA-Enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory

Biotech NewswireApril 26, 2024

Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

PharmaSourcesApril 18, 2024

UK regulator says COVID-19 prevention trial of hydroxychloroquine can resume | Pharmasources.com

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

PharmaSourcesApril 17, 2024

Company is targeting pancreatic cancer pain with advanced nerve detection and treatment technology

UK regulator says COVID-19 prevention trial of hydroxychloroquine can resume

Related News

InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

Touchlight Awarded Grant Extension to Further Develop DNA-Enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory

Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

You may like